Journals / Van Tıp Dergisi / 2021 / Cilt: 28 - Sayı: 2

Intraocular Pressure Assessment in Pediatric Cases Receiving Long-Term Seasonal Allergic Conjunctivitis Treatment

Uzun Süreli Mevsimsel Alerjik Konjonktivit Tedavisi Alan Pediatrik Olgularda Göz İçi Basıncı Değerlendirmesi

Pages
227–231
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We think that close follow-up is important to realize possible acute IOP elevation in these patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To investigate the effect of seasonal drugs on intraocular pressure (IOP) in the long term in pediatric age group who are followed up and treated with seasonal allergic conjunctivitis (SAC) diagnosis.
📊
Key Findings & Data:Materials and Methods: The study included 230 cases under the age of 16 who received SAC treatment for 5 years or more (Group I), and 255 healthy cases under the age of 16 in the control group (Group II).
💡
Conclusion & Impact:We think that close follow-up is important to realize possible acute IOP elevation in these patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: To investigate the effect of seasonal drugs on intraocular pressure (IOP) in the long term in pediatric age group who are followed up and treated with seasonal allergic conjunctivitis (SAC) diagnosis. Materials and Methods: The study included 230 cases under the age of 16 who received SAC treatment for 5 years or more (Group I), and 255 healthy cases under the age of 16 in the control group (Group II). IOP measurements of the patients were made with non-contact tonometry. Mean IOP values of both groups were statistically compared. Results: The mean age of the patients included in the study was 9.3±2.0 in group I and 9.1±2.1 in group II. The mean duration of treatment in SAC patients was 5.3±0.7 years. In group I, the mean IOP was 13.7±3.1 mmHg in the right eye, 13.7±2.8 mmHg in the left eye, while in group II the mean IOP was 13.8±3.1 mmHg in the right eye and 13.9±3.0 mmHg in the left eye. There was no statistically significant difference between the mean IOP values of two groups (P>0.05). Temporary IOP elevation due to corticosteroid treatment was observed in 11 patients (4.8%) in group I. In all these patients, IOP lowered to normal limits after corticosteroid treatment discontinued. Conclusion: It was observed that medical treatment, which is given periodically with the diagnosis of SAC in pediatric cases, does not have a permanent effect on IOP in the long term. We think that close follow-up is important to realize possible acute IOP elevation in these patients.

Özet

Amaç: Mevsimsel alerjik konjonktivit (MAK) tanısı ile takip ve tedavi edilen pediatrik yaş grubu hastalarda, dönemsel olarak kullanılan ilaçların uzun dönemde göz içi basıncı (GİB) üzerine olan etkisini araştırmak. Gereç ve Yöntemler: Çalışmaya 16 yaş altında, 5 yıl veya daha fazla süredir MAK tedavisi alan 230 olgu (Grup I) ve kontrol grubuna 16 yaş altında sağlıklı 255 olgu (Grup II) dahil edildi. Hastaların GİB ölçümleri non-kontakt tonometri ile yapıldı. Her iki grubun ortalama GİB değerleri istatistiksel olarak kıyaslandı. Bulgular: Çalışmaya alınan olguların yaş ortalaması grup I'de 9.3±2.0, grup II'de 9.1±2.1 bulundu. Grup I'de hastaların MAK nedeni ile tedavi aldıkları süre ortalama 5.3±0.7 yıldı. Grup I'de ortalama GİB sağ gözde 13.7±3.1 mmHg, sol gözde 13.7±2.8 mmHg bulunurken, grup II'de ortalama GİB sağ gözde 13.8±3.1 mmHg, sol gözde 13.9±3.0 mmHg olarak bulundu. İki grubun ortalama GİB değerleri arasında istatistiksel olarak anlamlı fark olmadığı görüldü (P>0.05). Grup I'de 11 hastada (% 4.8) tedavi esnasında kortikosteroid kullanımına bağlı geçici GİB yükselmesi olduğu gözlendi. Bu hastaların tümünde kortikosteroid kesildikten sonra GİB normale döndü. Sonuç: Pediatrik olgularda MAK tanısıyla dönemsel olarak verilen medikal tedavinin uzun dönemde GİB üzerine kalıcı bir etkisinin olmadığı görüldü. Bu hastalarda olası akut GİB yükselmesini fark etmek için yakın takibin önemli olduğunu düşünmekteyiz.

🔖

Cite This Article

TANRIVERDİ, C., DEMİRCİ, G., ERDUR, S. K., BALCI, Ö., ÖZSÜTÇÜ, M., ARAS, C., TABAKÇI, B. N. (2022). Intraocular Pressure Assessment in Pediatric Cases Receiving Long-Term Seasonal Allergic Conjunctivitis Treatment. Van Tıp Dergisi, Cilt: 28 - Sayı: 2, 227–231. https://ajindex.com/articles/645930

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Burcu A, Nurözler Tabakcı B. Allergy and Dry Eye. MN Oftalmoloji 2016; 23: 72-82
  2. Wallace DV, Dykewicz MS, Bernstein DI, Blessing-Moore J, Cox L, Khan DA et al. The diagnosis and management of rhinitis: an update practice parameter. J Allergy Clin Immunol 2008; 122: 1-84
  3. Owen CG, Shah A, Henshaw K, Smeeth L, Sheikh A. Topical treatments for seasonal allergic conjunctivitis: systematic review and meta-analysis of efficacy and effectiveness. Br J Gen Pract. 2004; 54 (503): 451-456
  4. Bielory L, Meltzer EO, Nichols KK, Melton R, Thomas RK, Bartlett JD. An algorithm for the management of allergic conjunctivitis. Allergy Asthma Proc 2013; 34 (5): 408-420
  5. Canonica GW. Treating asthma as an inflammatory disease. Chest 2006; 130: 21-28
  6. Takamura E, Uchio E, Ebihara N, Ohno S, Ohashi Y, Okamoto S; Japanese Society of Allergology. Japanese guidelines for allergic conjunctival diseases 2017. Allergol Int 2017; 66 (2): 220-229
  7. Leonardi A. Emerging drugs for ocular allergy. Expert Opin Emerg Drugs 2005; 10 (3): 505-520
  8. Ilyas H, Slonim CB, Braswell GR, Favetta JR, Schulman M. Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis. Eye Contact Lens 2004; 30 (1): 10-13
  9. Kitamura Y, Miyoshi A, Murata Y, Kalubi B, Fukui H, Takeda N. Effect of glucocorticoid on upregulation of histamine H1 receptor mRNA in nasal mucosa of rats sensitized by exposure to toluene diisocyanate. Acta Otolaryngol 2004; 124 (9): 1053-1058
  10. Fukui H. Progress in allergy signal research on mast cells: up-regulation of histamine signal-related gene expression in allergy model rats. J Pharmacol Sci 2008; 106 (3): 325-331
  11. Chambless SL, Trocme S. Developments in ocular allergy. Curr Opin Allergy Clin Immunol 2004; 4 (5): 431-434
  12. Pleyer U, Ursell PG, Rama P. Intraocular pressure effects of common topical steroids for post-cataract inflammation: are they all the same? Ophthalmol Ther 2013; 2 (2): 55-72
  13. Cantrill HL, Palmberg PF, Zink HA, Waltman SR, Podos SM, Becker B. Comparison of in vitro potency of corticosteroids with ability to raise intraocular pressure. Am J Ophthalmol 1975; 79 (6): 1012-1017
  14. Bodor N. Novel approaches to the design of safer drugs: soft drugs and site-specific chemical delivery systems. Adv Drug Res 1984; 13: 255-331
  15. Bodor N. Soft drugs: principles and methods for the design of safe drugs. Med Res Rev 1984; 4 (4): 449-469
  16. Druzgala P, Wu WM, Bodor N. Ocular absorpti